Télécharger

Texte intégral

• Kanis JA, Johnell O, Oden A, et al. - Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int, 2000, 11, 669-674.
• Melton LJ 3rd, Chrischilles EA, Cooper C, et al. - How many women have osteoporosis? J Bone Miner Res, 2005, 20, 886-892.
• Center JR, Nguyen TV, Schneider D, et al. - Mortality after all major types of osteoporotic fracture in men and women : an observational study. Lancet, 1999, 353, 878-882. (Pubitemid 29126875)
• Cree M, Soskolne CL, Belseck E, et al. - Mortality and institutionalization following hip fracture. J Am Geriatr Soc, 2000, 48, 283-288. (Pubitemid 30164211)
• Autier P, Haentjens P, Bentin J, et al. - Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int, 2000, 11, 373-380.
• Keene GS, Parker MJ, Pryor GA. - Mortality and morbidity after hip fractures. BMJ, 1993, 307, 1248-1250.
• Johnell O, Kanis JA, Oden A, et al. - Mortality after osteoporotic fractures. Osteoporos Int, 2004, 15, 38-42.
• Melton LJ 3rd, Gabriel SE, Crowson CS, et al. - Cost-equivalence of different osteoporotic fractures. Osteoporos Int, 2003, 14, 383-388.
• Reginster JY, Gillet P, Ben Sedrine W, et al. - Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics, 1999, 15, 507-514. (Pubitemid 29210953)
• Lekkerkerker F, Kanis JA, Alsayed N, et al. - Adherence to treatment of osteoporosis : a need for study. Osteoporos Int, 2007, 18, 1311-1317.
• Kanis JA, Johnell O, De Laet C, et al. - A meta-analysis of previous fracture and subsequent fracture risk. Bone, 2004, 35, 375-382. (Pubitemid 38953182)
• Klotzbuecher CM, Ross PD, Landsman PB, et al. - Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res, 2000, 15, 721-739.
• Lauritzen J, Schwarz P, Nair MC, Lund B. - Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women and their seasonal variation. Osteoporosis Int, 1993, 3, 133-137. (Pubitemid 23125374)
• Rabenda V, Vanoverloop J, Fabri V, et al. - Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am, 2008, 90, 2142-2148.
• Iborra J, Pages E, Rodriguez S, Cuxart A. - Missed diagnosis and treatment of osteoporosis in elderly patients with hip fracture. Bone, 2000, 5 (suppl), 252.
• Suarez-Almazor M, De Geus C, Homik J, Russel AS. - Failure to assess or manage osteoporosis following a hip fracture. Arthritis Rheum, 2000, 43 (suppl 9), S203.
• Khan SS, De Geus C, Holroyd B, Russel AS. - Osteoporosis follow up after low trauma wrist fractures. Arthritis Rheum, 2000, 43 (suppl 9), S200.
• Cuddihy MT, Gabriel SE, Crowson CS, Atkinston E. - Osteoporosis management in postmenopausal women after low impact distal forearm fracture : a missed opportunity. J Bone Miner Res, 2000, 15, 187.
• Torgerson DJ, Dolan P. - Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis, 1998, 57, 378-379. (Pubitemid 28378316)
• Castel H, Bonneth DY, Sherf M, Liel Y. - Awaraness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporosis Int, 2001, 12, 559-564. (Pubitemid 32777432)
• Black DM, Cummings SR, Karpf DB, et al, for the fracture intervention trial group. - Randomised trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Lancet, 1996, 348, 1535-1541.
• Harris ST, Watts NB, Genant HK, et al. - Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. A randomised trial. JAMA, 1999, 282, 1344-1352.
• Chapuy MC, Arlot ME, Duboeuf F, et al. - Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J M, 1992, 327, 1637-1642.
• Lufkin EG, Wahner HW, O'fallon WH, et al. - Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern M, 1992, 117, 1-9.
• Ettinger B, Black DM, Mitlak BH, et al. - Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA, 1999, 282, 637-645.
• Mc Lung MR, Geusens P, Miller PD, et al. - For the hip intervention program study group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl, 2001, 344, 333-340.
• Kanis JA, Burlet N, Cooper C, et al, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). - European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int, 2008, 19, 399-428.
• Rabenda V, Hiligsmann M, Reginster JY. - Poor adherence to oral bisphosphonate treatment and its consequences : a review of the evidence. Expert Opin Pharmacother, 2009, 10, 2303-2315.
• Tosteson AN, Grove MR, Hammond CS, et al. - Early discontinuation of treatment for osteoporosis. Am J Med, 2003, 115, 209-216.
• Petrella RJ, Jones TJ. - Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? BMC Fam Pract, 2006, 7, 31.
• Grant AM, Avenell A, Campbell MK, et al. - Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD) : a randomised placebo-controlled trial. Lancet, 2005, 365, 1621-1628.
• Jackson RD, LaCroix AZ, Gass M, et al. - Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med, 2006, 354, 669-683. (Pubitemid 43247138)
• Rabenda V, Mertens R, Fabri V, et al. - Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int, 2008, 19, 811-818.
• Siris ES, Harris ST, Rosen CJ, et al. - Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc, 2006, 81, 1013-1022.
• Tang BM, Eslick GD, Nowson C, et al. - Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet, 2007, 370, 657-666.
• Reginster JY. - Calcium and vitamin D for osteoporotic fracture risk. Lancet, 2007, 370, 632-634. (Pubitemid 47299247)
• Sullivan S, Kreling D, Hazlet TH. - Non-compliance with medication regimens and subsequent hospitalizations : a literature analysis and cost of hospitalization estimate. J Res Pharmac Econom, 1990, 2, 19-33.
• Miller NH. - Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med, 1997,102, 43-49. (Pubitemid 27147947)
• Hiligsmann M, Rabenda V, Bruyère O, Reginster JY. - The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy, 2010, Feb 12 [Epub ahead of print].
• Simpson SH, Eurich DT, Majumdar SR, et al. - A meta-analysis of the association between adherence to drug therapy and mortality. BMJ, 2006, 333, 15.
• Rossini M, Bianchi G, Di Munno O, et al. - Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int, 2006, 17, 914-921. (Pubitemid 43781506)
• Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. - Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther, 2006, 28, 236-242.
• Ettinger B, Pressman A, Schein J, et al. - Alendronate Use Among 812 Women: Prevalence of Gastrointestinal Complaints, Noncompliance with Patient Instructions, and Discontinuation. J Manag Care Pharm, 1998, 4, 488-492.
• Gray SL, Mahoney JE, Blough DK. - Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother, 1987, 35, 539-545.
• Hussey LC. - Overcoming the clinical barriers of low literacy and medication non-compliance among the elderly. J Gerontol Nurs, 1991, 17, 27-29.
• Emkey R, Koltun W, Beusterien K, et al. - Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial : the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin, 2005, 21, 1895-1903. (Pubitemid 41803098)
• Cooper A, Drake J, Brankin E, the PERSIST Investigators. - Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract, 2006, 60, 896-905. (Pubitemid 44082279)
• McClung M, Recker R, Miller P, et al. - Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone, 2007, 41, 122-128.
• Reginster JY, Deroisy R, Neuprez A, et al. - Strontium ranelate : new data on fracture prevention and mechanisms of action. Curr Osteoporos Rep, 2009, 7, 96-102.
• Rabenda V, Reginster JY. - Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos Int, 2010, Jan 16 [Epub ahead of print].
• Delmas PD, Vrijens B, Roux C, et al. - Reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. J Bone Miner Res, 2003, 2 (suppl), S374.
• Clowes JA, Peel N, Eastell R. - The impact of monitoring adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab, 2004, 89, 1117-1123. (Pubitemid 38368399)
• Pickney CS, Arnason JA. - Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int, 2005, 16, 1156-1160.